✉news HealthMedicine first seen 5 h ago, last 3 h ago, peak #26
Vyriad Launches First-in-Human Trial of CAR T Therapy VV169
Original: Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
Biotech company Vyriad has begun the first-in-human clinical trial of VV169, an in vivo CAR T therapy that engineers immune cells inside the patient's body rather than in a lab. The early-stage trial marks a first step in testing the safety of the experimental cancer treatment in people, an approach watched closely as it could simplify a cell therapy process that is currently complex and costly.
Why now: First-in-human trials of novel cancer therapies draw attention from investors, clinicians and patients tracking the next generation of cell therapy.
Rank over time, top of the chart is #1. 2 snapshots from 5 h ago to 3 h ago.
Evidence
- Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169 · The Medicine Maker
API: https://socialmediatrends-api.osmike.com/v1/trends/236687